Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
Allergan Inc., Pfizer Inc. and other drug makers won their bid to dismiss a consumer class suit alleging the companies’ glaucoma eye drops were unnecessarily large, resulting in too high a price ( Eike v. Allergan, Inc. , 7th Cir., No. 16-3334, 3/6/17 ).
Judge Richard A. Posner of the U.S. Court of Appeals for the Seventh Circuit March 6 vacated a district court order that certified the consumer suit as a class action. He remanded the matter to the district court with directions that it be dismissed.
Charlene Eike contended she and other class members overpaid because of the size of the drops.
The companies challenged a decision by the U.S. District Court for the Southern District of Illinois that said the plaintiffs could sue as a group.
Posner said the plaintiffs’ claims were doomed in part by the Food and Drug Administration’s approval of the drops—a determination they were safe and effective to treat glaucoma.
A court can’t bypass the agency and make its own safety and efficacy determination, Posner said.
Additionally, he said the plaintiffs wouldn’t have standing, or reason to sue, even if it could be shown that a smaller eye drop would be cheaper and more effective than the ones they bought.
Standing requires an actual injury to the plaintiffs, he said.
The fact that a seller doesn’t sell the product you want, or at the price you want to pay, isn’t an actionable injury, Posner said.
The Law Office of Richard S. Cornfeld and others represented the plaintiffs.
Hepler Broom LLC and Shook, Hardy & Bacon LLP represented Allergan.
To contact the reporter on this story: Julie A. Steinberg in Washington at email@example.com
To contact the editor responsible for this story: Steven Patrick at firstname.lastname@example.org
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)